Paul Kirkham (Wolverhampton, United Kingdom), Alexander Mathioudakis (Liverpool, United Kingdom), Kian Fan Chung (London, United Kingdom), Nicolas Roche (Paris, France)
Compare clinical effectiveness of various types of bronchodilators in COPD patients
Tatiana Germanovna Shapovalova (Saratov, Saratov Oblast, Russian Federation), Tatiana Germanovna Shapovalova, Nina Andreevna Ivaniva, Elena Evgenyevna Arhangelskaya, Elena Sergeevna Plastinina, Natalia Vladimirovna Shelobanova, Olga Aleksandrovna Ponomareva, Marina Viktorovna Margasova, Anna Yrievna Ryabova, Marina Mikhailovna Shashina
|   |
Outcome of patients following hospitalization with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) , with and without cardiovascular risk factors
Saadia Ashraf (Peshawar, Pakistan), Saadia Ashraf, Amber Ashraf, Mukhtiar Zaman
| |
Long-term inhaled corticosteroid use in COPD and the risk of fracture in men and women
Samy Suissa (Montreal, Canada), Samy Suissa, Janie Coulombe, Pierre Ernst
| |
Secondary analysis of the UPLIFT® trial by body mass index
Donald P Tashkin (Los Angeles, United States of America), Donald P. Tashkin, Antonio Anzueto, Norbert Metzdorf, Achim Mueller, Ulrika Hinkel, Bartolome Celli
| |
Eosinophilic airway inflammation as a complication of COPD, and the usefulness of ICS on these cases
Hiroaki Kume (Osakasayama, Japan), Hiroaki Kume, Osamu Nishiyama, Yuji Higashimoto, Yuji Tohda
| |
The effect of aclidinium bromide 400 µg on sleep quality in COPD: A pilot study
Helgo Magnussen (Großhansdorf, Germany), Helgo Magnussen, Michael Arzt, Stefan Andreas, Tanja Plate, Anna Ribera, Beatriz Seoane, Henrik Watz, Anne-Marie Kirsten
| |
RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients
Katharine Abbott-Banner (London, United Kingdom), Dave Singh, Kathy Banner, Kenneth Newman
| |
Effect of tiotropium compared to salmetrol on dynamic hyperinflation in patients with chronic obstructive pulmonary disease
Khalil Ansarin (Tabriz, Islamic Republic of Iran), Khalil Ansarin, Payam Salehirad, Mohammadamin Rezazadehsaatlou
| |
Usefulness of severity predictive scores in COPD exacerbations in hospitalized patients
Elena Cabezas Pastor (Madrid, Spain), Elena Cabezas Pastor, Andrés Giménez Velando, Herminia Ortiz Mayoral, Reyes Calzado López, María Teresa Pérez Warnisher, Diana Sánchez Mellado, Germán Peces-Barba Romero, Felipe Villar Álvarez
| |
Severity of airflow obstruction and multicomponent disease staging of COPD in the real-world primary care in Greece: The AEOLUS study
Eirini Mitsiki ( Athens, Greece), Eirini Mitsiki, Mina Gaga, Niki Georgatou-Papageorgiou, Paraskevi Katsaounou, Epameinondas Kosmas, Nikolaos Koulouris, Elena Panitti, Nikolaos Siafakas, Paschalis Steiropoulos, Michail Toumpis, Nikolaos Tzanakis, Theodoros Vassilakopoulos
| |
Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study
Konstantinos Kostikas (Basel, Switzerland), Konstantinos Kostikas, Claus Vogelmeier, Timm Greulich, Jose M. Marin, Walter Castellani, Thomas Similowski, Vincent Ninane, Mina Gaga, Stephen Lane, Maryam Aalamian-Mattheis, Xavier Nunez, Andreas Clemens
| |
Assessing COPD profiles and outcomes by dyspnoea severity
Antonio R. Anzueto (San Antonio, United States of America), Antonio R. Anzueto, Peter M.A. Calverley, Robert A. Wise, Achim Mueller, Norbert Metzdorf, Daniel Dusser
| |
Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team
Angshu Bhowmik (Barnet, United Kingdom), Angshu Bhowmik, Arthur Tadique, Laura Graham, Matthew Hodson, Raj Rajakulasingam
| |
Onset of action of formoterol/budesonide (F/B) Spiromax® compared with F/B Turbuhaler® in patients with COPD: A preliminary report
Josuel Ora (Rome, Italy), Josuel Ora, Alessandra Di Paolo, Gabriella Lucà, Luigino Calzetta, Paola Rogliani, Mario Cazzola
| |
Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients
Kshitij Mandke (Surat, India), Kshitij Mandke, Anup Mandke
| |
Quantify comorbidities burden of chronic obstructive pulmonary disease patients using medication regimen complexity index
Wei-Erh Cheng (Taichung, Taiwan), Wei Erh Cheng, Shan Chieh Wu, Sandy Ian-U. Chong, Jou Ying Chen, Hsiang-Wen Lin
| |
Long-acting bronchodilators (LABDs) and major adverse cardiac events (MACE) in patients with COPD: A pooled analysis of 12 randomised trials
John R Hurst (London, United Kingdom), John R. Hurst, Samy Suissa, Klaus F. Rabe, Giovanni Bader, Gerrit Zijlstra, Marcela Gavornikova, Francesco Patalano, Robert Fogel, Konstantinos Kostikas
| |
Patient characteristics of new initiators of glycopyrronium bromide (GLY) – A multinational, multi-database real-world drug-utilization study
Katia MC Verhamme (Rotterdam, Netherlands), Katia M.C. Verhamme, Maria De Ridder, Lars Pedersen, Daniel Prieto-Alhambra, Francesco Lapi, Peter Rijnbeek, Rajeev K. Amar, Miriam Sturkenboom
| |
Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients
Fabrizia Mariotti (Parma, Italy), Fabrizia Mariotti, Sara Collarini, Stefano Vezzoli, Daniela Acerbi, Maxim Kots, Piotr Kuna
| |
Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients
Mario Scuri (Parma, Italy), Elzbieta Hajol, Annalisa Piccinno, Isabelle Viaud, Isabella Montagna, Alessandro Guasconi, Stefano Vezzoli, Mario Scuri, Mike Polkey
| |